University of California-San Francisco: Drug Prevents Multiple Sclerosis Relapses in Phase 3 Trial
August 05, 2020
August 05, 2020
SAN FRANCISCO, California, Aug. 5 -- The University of California San Francisco campus issued the following news release:
A newly completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS) - the most common form of the illness, in which symptoms wax and wane.
MS is an autoimmune disease in which the body's immune system attac . . .
A newly completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS) - the most common form of the illness, in which symptoms wax and wane.
MS is an autoimmune disease in which the body's immune system attac . . .